A PHASE 1, OPEN LABEL, NON-RANDOMIZED, MULTI-ARM, MULTI-CENTRE, PARALLEL SEQUENCE STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE AND THE DOSE LIMITING TOXICITY OF GENOPEP 1 (ISSAR 1) IN RELAPSED SOLID TUMOUR CANCER PATIENTS.

Trial Profile

A PHASE 1, OPEN LABEL, NON-RANDOMIZED, MULTI-ARM, MULTI-CENTRE, PARALLEL SEQUENCE STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE AND THE DOSE LIMITING TOXICITY OF GENOPEP 1 (ISSAR 1) IN RELAPSED SOLID TUMOUR CANCER PATIENTS.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Genopep 1; Genopep 1
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Issar Pharma
  • Most Recent Events

    • 24 Jul 2012 Status changed from recruiting to completed as reported by Clinical Trials Registry - India.
    • 16 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top